NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03095040,CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma,https://clinicaltrials.gov/study/NCT03095040,,UNKNOWN,"This randomized, double blind, phase 2/3 study is aimed to evaluate the efficacy and safety of CM082 in combination with everolimus in Chinese patients with advanced renal cell carcinoma. The primary endpoint is progression-free survival.",NO,Renal Cell Cancer Metastatic,DRUG: CM082 combined with everolimus|DRUG: CM082|DRUG: Everolimus,"Progression-free survival, The internal between the date of randomization and the date of disease progression, unaccepted toxicity, or death, 12 months","Overall survival, The internal between the date of randomization and the date of death, 36 months|Objective response rate, The percentage of patients with tumor response in overall population, 8 weeks",,AnewPharma,,ALL,"ADULT, OLDER_ADULT",PHASE3,390,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",CM082-CA-â…¡-201,2016-12-16,2021-02,2021-12,2017-03-29,,2021-02-08,"Beijing Cancer Hospital, Beijing, Beijing, 100142, China",
